-
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
03 Apr 2025 11:30 GMT
… into an acquisition agreement with GlycoMimetics, Inc. (Nasdaq: GLYC). Following … led the company through its initial public offering (IPO) and advanced two rare muscle … leading both companies through their IPOs while progressing their product candidates …
-
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
31 Mar 2025 11:00 GMT
… of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (“IPO”) on …
-
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
07 May 2021 11:52 GMT
… to its first-quarter results)
GlycoMimetics, Inc. (NASDAQ: GLYC)
… (before the market open)
IPOs
Talaris Therapeutics, Inc., a late … therapy company priced its initial public offering of 8.825 million … substance addiction, priced its IPO of 3 million shares …
-
Avacta Appoints Brian Hahn as Chief Financial Officer
13 Jan 2025 12:00 GMT
… of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (IPO) on … , having been involved in multiple IPOs, and has raised over $700 … his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of …
-
The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix
21 Sep 2020 01:26 GMT
… 18, with conference presentations, IPO news flow and updates on … with Type 1 diabetes.
GlycoMimetics Inc. (NASDAQ: GLYC) will … (Thursday, after the close)
IPOs
Woodcliff Lake, New Jersey-based … 2.5-million share initial public offering, or IPO. It is a clinical …
-
The Investment Case For GlycoMimetics
17 Nov 2020 11:47 GMT
… paragraphs below. Company Overview GlycoMimetics (GLYC) IPO’d in 2014 and is … disorders from inflammation to cancer. GlycoMimetics is using their unique understanding … clinical programs, Rivipansel and Uproleselan. GlycoMimetics has a market capitalization of …
-
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation
06 Oct 2020 12:47 GMT
… Sept. 24)
Stocks In Focus
GlycoMimetics's Sickle Cell Disease … Gets Rare Pediatric Disease Designation
GlycoMimetics Inc (NASDAQ: GLYC) said the … , Alkermes Adcom Meeting, Aziyo Biologics IPO
Gamida Cell Reports Positive Late …
-
Week In Review: Zai Lab Completes Second Listing With $761 Million HK IPO
04 Oct 2020 21:48 GMT
… million in a Hong Kong IPO and rose 8.5% in … rights to the candidate from GlycoMimetics (NASDAQ:GLYC) of the US …
-
The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO
01 May 2020 12:19 GMT
… : ABBV) (before the market open)
GlycoMimetics Inc (NASDAQ: GLYC) (before the … : IMGN) (before the market open)
IPO
Lyra Therapeutics, a clinical-stage … and throat diseases, priced its initial public offering of 3.5 million shares …
-
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
28 Feb 2020 12:42 GMT
… open)
GlycoMimetics Inc (NASDAQ: GLYC) (before the market open)
IPO
Passage Bio …
About
© 1995-2025